| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23002 |
| Drug |
Lutetium (177Lu) vipivotide tetraxetan |
| Brand |
Pluvicto® |
| Indication |
Lutetium (177Lu) vipivotide tetraxetan in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. |
| Rapid review commissioned |
09/01/2023 |
| Rapid review completed |
10/02/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/03/2023 |
| Pre-submission consultation with Applicant |
09/05/2023 |
| Full submission received from Applicant |
19/07/2023 |
| Preliminary review sent to Applicant |
06/02/2024 |
| NCPE assessment re-commenced |
05/03/2024 |
